Celltrion to Announce Achievements in New Drug Development and CMO Business Vision

Growth Strategy Unveiled at JP Morgan Healthcare Conference

Celltrion announced on January 7 that it will present its achievements in new drug development and its future contract manufacturing (CMO) business strategy at the 2026 JP Morgan Healthcare Conference (JPM), the world’s largest pharmaceutical and biotech investment event.

Celltrion

Now in its 44th year, JPM is the largest investment event where pharmaceutical and biotech companies from around the world gather with global investors. It will be held from January 12 to 15 (local time) at The Westin St. Francis Hotel in San Francisco, California, USA. More than 8,000 global investors and industry professionals are expected to attend this year’s event.

Celltrion has been selected as a main track presenter, the core stage of the event. The presentation will take place at 3:45 p.m. on January 13 in the hotel’s Grand Ballroom. Seo Jinseok, CEO of Celltrion, will introduce the company’s new drug development roadmap, including both its achievements to date and undisclosed pipeline assets, based on the development timeline of its new drug pipeline. In the biosimilar segment, Celltrion will also outline the stepwise product launch timeline and strategies to expand into global target markets. After the presentation, Celltrion plans to directly engage in an on-site Q&A session with global investors.

Following this, Executive Vice President Lee Hyukjae will announce the company’s strategy to build an end-to-end U.S. supply chain centered on the recently acquired manufacturing facility in Branchburg, New Jersey, as well as plans to expand its CMO business through this initiative.

Celltrion is accelerating new drug development focused on antibody-based modalities such as antibody-drug conjugates (ADC) and multi-specific antibodies, leveraging the technology and expertise it has accumulated through developing the world’s first antibody biosimilar. By utilizing its U.S. manufacturing facility, Celltrion is mitigating tariff risks and strengthening its global supply stability and market responsiveness to address its growing product portfolio. At this year’s JPM, Celltrion’s competitive pipeline for new drugs, the scalability of its biosimilar products, and its global production and supply strategy are expected to be key points of interest for investors.

A Celltrion representative stated, “Through this JPM presentation, we plan to present a more concrete strategy for future revenue growth, focusing on achievements in new drug development, expansion of new products, and the CMO business,” adding, “By combining our competitive antibody technology and global manufacturing capabilities, we will clearly communicate our business direction to investors to achieve sustainable growth in the global market.”